A notable example is the ARETTA (Assessing Response to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women With HER2-positive Breast Cancer) study, an ongoing clinical trial assessing the response to trastuzumab and taxanes among black women with early-stage breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.